anti-inflammatoty and immuno-therapy - versus standard of care - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.94 [0.89, 1.00]< 110%45 studies (45/-)98.3 %some concerncritical moderatecrucial-
deaths 0.91 [0.87, 0.95]< 111%68 studies (68/-)100.0 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.89 [0.73, 1.09]< 117%7 studies (7/-)87.0 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.78 [0.63, 0.97]< 10%11 studies (11/-)98.7 %some concerncritical moderateimportant-
clinical improvement 1.45 [1.05, 2.00]> 163%10 studies (10/-)98.8 %some concernlow moderateimportant-
clinical improvement (14-day) 2.55 [0.81, 8.02]> 158%4 studies (4/-)94.5 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.66 [0.75, 3.67]> 164%4 studies (4/-)89.5 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 2.11 [0.90, 4.94]> 146%3 studies (3/-)95.7 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.56 [1.02, 2.39]> 149%5 studies (5/-)98.0 %some concernserious moderateimportant-
death or ventilation 0.93 [0.88, 0.98]< 156%15 studies (15/-)99.7 %some concernlow moderateimportant-
hospital discharge 1.06 [0.98, 1.14]> 171%7 studies (7/-)93.1 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.89 [0.80, 0.98]< 125%21 studies (21/-)99.1 %some concerncritical moderateimportant-
mechanical ventilation (time to event analysis only) 0.97 [0.62, 1.52]< 10%2 studies (2/-)55.5 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 3.02 [1.77, 5.14]> 10%3 studies (3/-)100.0 %some concernnot evaluable moderateimportant-
viral clearance 3.87 [1.04, 14.37]> 176%5 studies (5/-)97.8 %some concernnot evaluable moderateimportant-
viral clearance by day 14 1.08 [0.07, 16.52]> 197%5 studies (5/-)52.2 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.59 [0.67, 3.76]> 173%4 studies (4/-)85.4 %some concernnot evaluable moderateimportant-
ICU admission 0.86 [0.65, 1.14]< 10%9 studies (9/-)85.0 %some concernserious moderatenon important-
recovery 0.64 [0.14, 2.92]> 10%1 study (1/-)28.3 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 1.22 [1.05, 1.41]< 10%12 studies (12/-)0.5 %some concernlow moderateimportant-
superinfection 0.18 [0.02, 1.59]< 10%1 study (1/-)93.8 %NAnot evaluable important-
adverse events 1.50 [1.09, 2.06]< 133%10 studies (10/-)0.7 %some concerncritical moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.